Lunai Bioworks Inc. Announces Landmark Study Identifying Prognostic Biomarkers in Duchenne Muscular Dystrophy

Reuters
Oct 16
<a href="https://laohu8.com/S/LNAI">Lunai Bioworks</a> Inc. Announces Landmark Study Identifying Prognostic Biomarkers in Duchenne Muscular Dystrophy

Lunai Bioworks Inc. announced the publication of a new clinical study in Nature Communications, identifying serum protein biomarkers that can predict functional decline in Duchenne Muscular Dystrophy (DMD). The study, conducted by a multi-institutional team including Leiden University Medical Center, the University of Florida, and BioSymetrics Inc., analyzed over 700 longitudinal serum samples using the SomaScan® proteomics platform. The findings, which have already been presented in the published article, highlight the potential for these biomarkers to inform individual patient trajectories and enhance clinical trial design. BioSymetrics provided analytical support and led the integration of clinical and proteomic data for the project.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1086688) on October 16, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10